← Back to Clinical Trials
Recruiting Phase 2 NCT06065202

NCT06065202 Personalized Nutrition to Improve Recovery in Trauma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06065202
Status Recruiting
Phase Phase 2
Sponsor Duke University
Condition Abdominal Trauma
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2024-04-12
Primary Completion 2027-03-30

Eligibility & Interventions

Sex All sexes
Min Age 15 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Nutrition Supplement

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 150 participants in total. It began in 2024-04-12 with a primary completion date of 2027-03-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to determine if a particular method of providing nutrition improves the outcomes of patients in the intensive care unit (ICU) who have undergone abdominal surgery following trauma and would require nutrition delivered via the bloodstream (called total parenteral nutrition or TPN). The nutrition method being tested is a structured nutrition delivery plan, called the SeND Home pathway, that involves TPN, oral nutrition supplements, and the use of a device (called an indirect calorimeter or IC) to measure calorie needs. Participants will be randomly assigned (like the flip of a coin) to the SeND Home program or standard of care nutrition. In the SeND Home program, participants will receive TPN, followed by oral nutrition supplements (shakes) for 4 weeks after discharge. The control group will follow standard of care nutrition delivery that begins during ICU stay and concludes at hospital discharge. Participants in both groups will undergo non-invasive tests that measure how much energy (calories) they are using, body composition, and muscle mass and complete walking and strength tests, and surveys about quality of life.

Eligibility Criteria

Inclusion Criteria: * 15+ years old * Penetrating abdominal trauma requiring emergent major abdominal surgery * Admitted to the surgical ICU * Not expected to receive oral nutrition for 72 hours or more Exclusion Criteria: * Patients who are unable to ambulate at baseline * Expected withdrawal of life-sustaining treatment within 48 hours * Prisoners * Positive pregnancy test for women of child bearing potential.

Contact & Investigator

Central Contact

Krista Haines, MD

✉ krista.haines@duke.edu

📞 919-681-3784

Principal Investigator

Paul Wischmeyer, MD

PRINCIPAL INVESTIGATOR

Duke

Frequently Asked Questions

Who can join the NCT06065202 clinical trial?

This trial is open to participants of all sexes, aged 15 Years or older, studying Abdominal Trauma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06065202 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT06065202 currently recruiting?

Yes, NCT06065202 is actively recruiting participants. Contact the research team at krista.haines@duke.edu for enrollment information.

Where is the NCT06065202 trial being conducted?

This trial is being conducted at Durham, United States.

Who is sponsoring the NCT06065202 clinical trial?

NCT06065202 is sponsored by Duke University. The principal investigator is Paul Wischmeyer, MD at Duke. The trial plans to enroll 150 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology